GlassScriptPhysician profile
Ian Rosbrugh
NPI 1851456990
$5,315.39
in general payments reported to CMS, 2019-2025
28 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $323 · 2021: $1,380 · 2022: $795 · 2023: $417 · 2024: $40.42 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,531.92 | 2019-2025 | |
| Axonics, INC. | $928.09 | 2021-2022 | |
| Astellas Pharma US INC | $606.64 | 2019-2023 | Veozah, Myrbetriq |
| Abbvie INC. | $411.39 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Coloplast Corp | $272.85 | 2019-2022 | |
| Medtronic, INC. | $232.39 | 2021-2024 | Truclear, Interstim, Ligasure |
| Pfizer INC. | $167.78 | 2019-2023 | |
| Caldera Medical, INC | $158.50 | 2021-2022 | |
| Urovant Sciences INC | $144.20 | 2021-2022 | |
| Medtronic USA, INC. | $142.21 | 2020 | |
| Coopersurgical, INC. | $110.12 | 2021 | |
| Hologic Sales and Service, LLC | $85.25 | 2019-2023 | Omni Hysteroscope, Acessa Provu System, Third Wave |
| Sumitomo Pharma America, INC. | $69.93 | 2023 | Myfembree |
| Valencia Technologies Corporation | $66.80 | 2025 | Ecoin Device Kit |
| Therapeuticsmd, INC. | $56.79 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $48.80 | 2021-2023 | Twirla |
| Merck Sharp & Dohme LLC | $34.83 | 2019-2020 | |
| Organon LLC | $34.23 | 2022-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $31.14 | 2019-2022 | |
| Exeltis, USA INC. | $30.63 | 2022-2023 | Slynd |
| Amag Pharmaceuticals, INC. | $27.21 | 2019 | |
| Allergan, INC. | $24.99 | 2019 | |
| Biogen, INC. | $23.35 | 2024 | |
| Shield Therapeutics INC | $17.15 | 2023 | Accrufer |
| Evofem Biosciences, INC. | $16.64 | 2021 | |
| Myovant Sciences INC. | $16.50 | 2022 | |
| Mayne Pharma Commercial LLC | $12.65 | 2023 | |
| Novo Nordisk INC | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Rosbrugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.